<DOC>
	<DOCNO>NCT02682511</DOCNO>
	<brief_summary>The purpose phase 2 multicenter , randomize , double-blind , placebo-controlled , study assess safety efficacy ifetroban patient diffuse cutaneous systemic SSc ( dcSSc ) SSc-associated pulmonary arterial hypertension ( SSc-PAH ) .</brief_summary>
	<brief_title>Oral Ifetroban Treat Diffuse Cutaneous Systemic Sclerosis ( SSc ) SSc-associated Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This study randomize , placebo-controlled , double-blind phase 2 trial patient dcSSc SSc-PAH . Twenty participant SSc-PAH 14 participant dcSSc randomize receive either oral ifetroban daily match placebo . Study participant treat 12 month , follow 30-day follow-up period . The study test whether ifetroban safe statistically superior placebo reduce effect disease month 12 explore ability ifetroban prevent reverse progression patient early disease duration reverse establish disease patient longer disease duration .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Pathologic Processes</mesh_term>
	<mesh_term>Scleroderma , Limited</mesh_term>
	<mesh_term>Ifetroban</mesh_term>
	<criteria>Diffuse Cutaneous Criterion : 1 . Systematic Sclerosis ( SSc ) , define use 2013 American College Rheumatology/ European Union League Against Rheumatism Classification Criteria dcSSc within 5 year follow initial diagnosis define onset first nonRaynaud symptom . SScPAH Criteria : 1 . Adults fulfil 2013 American College Rheumatology/ European Union League Against Rheumatism Classification Criteria confirm SScPAH ( limited dcSSc ) confirm via previous cardiac catheterization 2 . Stable oral therapy PAH least 30 day ( monotherapy combination ) 3 . New York Heart Association ( NYHA ) Class IIII Heart Failure 1 . Have diagnosis systemic sclerosis sine scleroderma ; 2 . Be less 18 year age great equal 65 year age ; 3 . Be pregnant , nursing , plan become pregnant ; 4 . Current plan treatment prostanoid therapy ; 5 . Current plan treatment rituximab pirfenidone ; 6 . Current plan corticosteroid therapy great 15mg per day prednisone prednisone equivalent ; 7 . Significant lung disease , define FVC &lt; 50 % predict DLCO &lt; 40 % predict ; 8 . Significant kidney disease , define Glomerular Filtration Rate ( GFR ) &lt; 60 ml/min ; 9 . Have moderate severe hepatic impairment ; 10 . Contraindication MRI ( e.g. , implant magnetic material , claustrophobia ) ; 11 . Known hypersensitivity gadolinium ; 12 . Any cause pulmonary hypertension World Health Organization ( WHO ) Group I associate SSc ; 13 . Use aspirin &gt; 81 mg per day last two week ; 14 . Use warfarin , heparin anticoagulant last 30 day ; 15 . Recent ( within 6 week ) myocardial infarction persistent atrial arrhythmia ; 16 . Have history allergy hypersensitivity ifetroban ; 17 . Have take investigational drug within 30 day study treatment administration ; 18 . Inability understand requirement study , inability understand speak English abide study restriction return require treatment assessment ; 19 . Be otherwise unsuitable study , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ifetroban</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Systemic Sclerosis</keyword>
</DOC>